Natera, Inc. (NASDAQ:NTRA) Short Interest Update

Natera, Inc. (NASDAQ:NTRA) saw a significant decline in short interest in January. As of January 15th, there was short interest totaling 3,456,165 shares, a decline of 27.2% from the December 31st total of 4,747,257 shares. Approximately 2.6% of the company’s stock are short sold. Based on an average trading volume of 1,229,522 shares, the short-interest ratio is presently 2.8 days. Based on an average trading volume of 1,229,522 shares, the short-interest ratio is presently 2.8 days. Approximately 2.6% of the company’s stock are short sold.

Natera Stock Performance

NASDAQ:NTRA opened at $231.14 on Friday. The firm’s 50-day moving average is $235.91 and its 200-day moving average is $193.80. The company has a market cap of $31.97 billion, a price-to-earnings ratio of -100.93 and a beta of 1.62. Natera has a 52-week low of $125.38 and a 52-week high of $256.36.

Natera (NASDAQ:NTRA) last released its quarterly earnings data on Friday, November 7th. The medical research company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.25). The firm had revenue of $592.18 million for the quarter, compared to the consensus estimate of $514.55 million. Natera had a negative net margin of 14.61% and a negative return on equity of 25.07%. The business’s revenue for the quarter was up 34.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.26) earnings per share. Equities analysts predict that Natera will post -1.49 EPS for the current year.

Insider Buying and Selling at Natera

In other news, insider Solomon Moshkevich sold 1,200 shares of the stock in a transaction on Wednesday, January 28th. The shares were sold at an average price of $237.66, for a total transaction of $285,192.00. Following the transaction, the insider owned 142,486 shares in the company, valued at $33,863,222.76. This represents a 0.84% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Michael Burkes Brophy sold 1,867 shares of the firm’s stock in a transaction dated Thursday, January 29th. The shares were sold at an average price of $230.40, for a total value of $430,156.80. Following the transaction, the chief financial officer owned 59,059 shares in the company, valued at approximately $13,607,193.60. This trade represents a 3.06% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 514,528 shares of company stock valued at $114,975,330. 5.63% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Natera

Hedge funds and other institutional investors have recently made changes to their positions in the business. Sound Income Strategies LLC boosted its position in shares of Natera by 20.0% during the 4th quarter. Sound Income Strategies LLC now owns 270 shares of the medical research company’s stock valued at $62,000 after acquiring an additional 45 shares in the last quarter. Savvy Advisors Inc. boosted its holdings in Natera by 3.1% during the fourth quarter. Savvy Advisors Inc. now owns 1,541 shares of the medical research company’s stock valued at $353,000 after purchasing an additional 46 shares in the last quarter. Siemens Fonds Invest GmbH boosted its holdings in Natera by 3.1% during the third quarter. Siemens Fonds Invest GmbH now owns 1,804 shares of the medical research company’s stock valued at $290,000 after purchasing an additional 54 shares in the last quarter. First Horizon Corp grew its stake in shares of Natera by 7.3% in the 4th quarter. First Horizon Corp now owns 931 shares of the medical research company’s stock valued at $213,000 after purchasing an additional 63 shares during the period. Finally, BOKF NA raised its holdings in shares of Natera by 1.9% in the 3rd quarter. BOKF NA now owns 3,733 shares of the medical research company’s stock worth $601,000 after buying an additional 69 shares in the last quarter. 99.90% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on NTRA. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Natera in a research report on Thursday, January 22nd. Guggenheim boosted their price objective on shares of Natera from $230.00 to $270.00 and gave the stock a “buy” rating in a research note on Monday, January 5th. Canaccord Genuity Group reiterated a “buy” rating on shares of Natera in a research note on Monday, January 12th. BTIG Research lifted their target price on shares of Natera from $230.00 to $260.00 and gave the stock a “buy” rating in a report on Friday, December 5th. Finally, JPMorgan Chase & Co. upped their price target on shares of Natera from $250.00 to $260.00 and gave the company an “overweight” rating in a report on Monday, December 15th. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $249.20.

More Natera News

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Natera announced completion of enrollment in the randomized ACES‑EMB heart‑transplant trial — a clinical milestone for the transplant franchise (Prospera) that de‑risks the program’s pathway to clinical readouts and potential uptake. Article Title
• Positive Sentiment: Wall Street coverage remains largely favorable: multiple firms maintain buy/outperform views and several have raised targets (MarketBeat summary shows consensus around a “Moderate Buy” and an average target near $249). This supports upside expectations if results and growth continue.
• Neutral Sentiment: Natera reported preliminary Q4 revenue (details in the alert). Preliminary figures may influence sentiment when the final quarter report and guidance are released; investors should watch the formal Q4 release for confirmation versus consensus. Preliminary Q4 Revenue
• Neutral Sentiment: Institutional ownership remains extremely high (~99.9%), which tends to stabilize the shareholder base but can also concentrate selling/Buying flows when large holders move. (Source: MarketBeat summary.) Institutional Data
• Negative Sentiment: Multiple insider sales by senior executives: CFO Michael Burkes Brophy sold several tranches (totaling 5,064 shares across Jan. 20–29) and CEO Steven Chapman sold several thousand shares (roughly 5,970 shares across Jan. 27–28). These trades total millions of dollars and may create short‑term selling pressure despite insiders retaining large residual stakes. CFO Form 4 CEO Form 4
• Negative Sentiment: Other insiders (John Fesko, Solomon Moshkevich) also sold smaller tranches. While each reduction is under ~1% of those insiders’ holdings, the cluster of sales amplifies negative signaling to the market. Fesko Form 4 Moshkevich Form 4

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.